Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
103Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $44.64M | $-9.74M | $-0.36 |
| 2024 | $47.54M | $-436.0K | $-0.02 |
| 2023 | $21.25M | $-16.05M | $-0.60 |
| 2022 | $1.53M | $-23.71M | $-0.95 |
| 2021 | $0.00 | $-17.35M | $-0.67 |
Social Signal Score
Earnings
Thu, Nov 12(in 3 months)
Consensus estimate $0.10 per share
Typical surprise +66.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$0.05 vs $0.02beat
- Thu, May 14$0.01 vs $-0.02beat
- Tue, Mar 24$-0.11 vs $0.03miss
- Thu, Nov 13$-0.02 vs $-0.08beat
- Thu, Aug 14$-0.11 vs $-0.06miss
- Tue, May 13$-0.04 vs $-0.12beat
Estimates and results for FENC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
FENChas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newsmarketbeat.com·4d ago·Neutral
Adherex Technologies Q2 Earnings Call Highlights Adherex Technologies NASDAQ: FENC, operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise.
View source ↗ - Newszacks.com·4d ago·Neutral
Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates Adherex Technologies Inc. (FENC) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to a loss of $0.11 per share a year ago.
View source ↗